Abstract
Purpose
To examine the risk for retinal-vein-occlusion (RVO) in patients with neovascular age-related-macular-degeneration (AMD) as compared to age- and sex-matched controls.
Method
This is a population-based, cohort study. The study encompassed 24,578 consecutive patients with neovascular AMD and 66,129 control subjects. Multivariate cox regression analysis was utilized to detect the risk of RVO among patients with neovascular AMD. Predictors of RVO in patients with neovascular AMD were identified using multivariate logistic regression analysis. Mortality of patients was assessed using Kaplan–Meier method.
Results
The incidence rate of RVO was estimated at 1.25 (95% CI, 1.06–1.45) per 1000 person-years among patients with neovascular AMD and 0.25 (95% CI, 0.20–0.31) per 1000 person-years among controls. Patients with neovascular AMD were associated with an increased risk of RVO (adjusted HR, 4.35; 95% CI, 3.34–5.66; P < 0.001). Among patients with neovascular AMD, older age (≥79.0 years) was associated with a decreased risk of RVO (adjusted OR, 0.50; 95% CI, 0.37–0.70; P < 0.001), whilst a history of glaucoma increased the likelihood of RVO (adjusted OR, 2.66; 95% CI, 1.94–3.65; P < 0.001). Patients with neovascular AMD and comorbid RVO had a comparable risk of all-cause mortality relative to other patients with neovascular AMD (HR, 0.90; 95% CI, 0.67–1.22; P = 0.500)
Conclusions
An increased risk of RVO was found among patients with neovascular AMD. Younger age and glaucoma predicted the development of RVO in patients with neovascular AMD. Awareness of this comorbidity is of benefit for clinicians as patients with neovascular AMD might be carefully examined for RVO signs and complications.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Data availability
It is not possible to share research data publicly, due to individual privacy. In case that necessary, as approval from the IRB as well as the patients will be needed.
References
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Heal. 2014;2:e106–16. https://doi.org/10.1016/S2214-109X(13)70145-1
Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet 2018;392:1147–59. https://doi.org/10.1016/S0140-6736(18)31550-2
Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): Relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol Asp Med. 2012;33:295–317. https://doi.org/10.1016/j.mam.2012.04.005
Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313–9.e1. https://doi.org/10.1016/j.ophtha.2009.07.017
Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia Parodi M, Lanzetta P, et al. Management of retinal vein occlusion - Consensus document. Ophthalmologica. 2011;226:4–28. https://doi.org/10.1159/000327391
Frangieh GT, Green WR, Barraquer Somers E, Finkelstein D. Histopathologic Study of Nine Branch Retinal Vein Occlusions. Arch Ophthalmol. 1982;100:1132–40. https://doi.org/10.1001/archopht.1982.01030040110020
Haymore JG, Mejico LJ. Retinal vascular occlusion syndromes. Int Ophthalmol Clin. 2009;49:63–79. https://doi.org/10.1097/IIO.0b013e3181a8db88
Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: Basic concepts, clinical features and management. Prog Retin Eye Res. 2008;27:622–47. https://doi.org/10.1016/j.preteyeres.2008.09.003
Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Association between schizophrenia and an autoimmune bullous skin disease-pemphigus: a population-based large-scale study. Epidemiol Psychiatr Sci. 2019;28:191–8. https://doi.org/10.1017/S204579601700052X
Kridin K, Amber K, Khamaisi M, Comaneshter D, Batat E, Cohen AD. Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study. Immunol Res. 2018;66:425–30. https://doi.org/10.1007/s12026-018-9005-8
Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol. 2014;2014:724780. https://doi.org/10.1155/2014/724780
Karia N. Retinal vein occlusion: Pathophysiology and treatment options. Clin Ophthalmol. 2010;4:809–16. https://doi.org/10.2147/opth.s7631
Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol. 1987;31:291–306. https://doi.org/10.1016/0039-6257(87)90115-9
Campochiaro PA, Akhlaq A Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Prog Retin Eye Res. https://doi.org/10.1016/j.preteyeres.2020.100921
Cugati S, Jie JW, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: The blue mountains eye study. Arch Ophthalmol. 2006;124:726–32. https://doi.org/10.1001/archopht.124.5.726
Recchia FM, Brown GC. Systemic disorders associated with retinal vascular occlusion. Curr Opin Ophthalmol. 2000;11:462–7. https://doi.org/10.1097/00055735-200012000-00013
Yau JWY, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: An approach to diagnosis, systemic risk factors and management. Intern Med J. 2008;38:904–10. https://doi.org/10.1111/j.1445-5994.2008.01720.x
Lang GE, Spraul CW. Risk factors for retinal vein occlusion. Tagl Prax. 2002;43:787–94. https://doi.org/10.1016/s0161-6420(92)31940-2
Haar CM Summary of Recommendations. In: Mastering Boston Harbor. National Institute for Health and Care Excellence (UK); 2015:311-4. https://doi.org/10.4159/9780674038097-023
Gale RP, Mahmood S, Devonport H, Patel PJ, Ross AH, Walters G, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye 2019;33:1. https://doi.org/10.1038/s41433-018-0300-3
Alexander CW. Time is now for retina exams to move from slit lamp to OCT biomicroscopy. Ocular surgery news. 2012.
Bremond-Gignac D. Investigational drugs for retinal vein occlusion. Expert Opin Investig Drugs. 2016;25:841–50. https://doi.org/10.1080/13543784.2016.1181750
Acknowledgements
ADC served as an advisor, investigator, or speaker for Abbvie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer, and Rafa. None of the other authors have any conflicts of interest to declare. No funding was provided for this manuscript. The manuscript has not been published elsewhere, has not been evaluated for publication previously by another journal, and was not submitted simultaneously for publication elsewhere.
Author information
Authors and Affiliations
Contributions
OW: Conception or design of the work, Data collection, Critical revision of the article, Final approval of the version to be published. MK: Data analysis and interpretation, Drafting the article, Final approval of the version to be published. KK: Conception or design of the work, Data collection, Data analysis and interpretation, Critical revision of the article, Final approval of the version to be published. OM: Critical revision of the article, Final approval of the version to be published. ADC: Conception or design of the work, Data collection, Critical revision of the article, Final approval of the version to be published. OZ: Conception or design of the work, Data analysis and interpretation, Drafting the article, Final approval of the version to be published.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Weinstein, O., Kridin, M., Kridin, K. et al. The risk of retinal vein occlusion among patients with neovascular age related macular degeneration: a large-scale cohort study. Eye 37, 1445–1450 (2023). https://doi.org/10.1038/s41433-022-02163-7
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-022-02163-7
This article is cited by
-
Exploring the role of oxidative stress in retinal vein occlusion: an updated and comprehensive review on the pathophysiology and treatment perspectives
International Ophthalmology (2025)
-
Demography, clinical profile and risk of retinal vein occlusion among patients with age-related macular degeneration – a tertiary hospital based study
Graefe's Archive for Clinical and Experimental Ophthalmology (2025)
